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administration with the greatest values observed for the for-
mer. All the studied formulas decreased the intact parathy-
roid hormone level in serum although the greatest change 
was observed for CaPyr and CaCarb. The administration 
of CaPyr induced gastrointestinal side effects, dyspepsia 
and diarrhea in 16.6 % of the studied individuals. No seri-
ous adverse events were noted. CaPyr demonstrates both 
a promising source of Ca and a potential for use in osteo-
porosis prevention. Further investigations should focus on 
the long-term dietary effects of CaPyr supplementation to 
assess its safety and potential beneficial effect on human 
Ca turnover.
Keywords Calcium supplementation · Dietary 
supplements · Bioavailability · Clinical trial
Introduction
Calcium (Ca) is a highly essential element whose intake in 
some populations is below the required recommendations. 
At the same time, being the most abundant mineral in the 
human body, it is necessary for muscle function, nerve 
transmission, intracellular signaling and vascular contrac-
tion and vasodilation. The majority of Ca (99 %) is present 
in teeth and bones in a chemical form of hydroxyapatite 
[Ca10(PO4)6(OH)2] with the rest circulating in extracel-
lular fluids and plasma and deposited in soft tissues and 
organs. This internal Ca balance is mediated by vitamin D 
and parathyroid hormone [1, 2]. The most important human 
pathology resulting from lowered Ca intakes or poor Ca 
absorption is osteoporosis—a skeletal disorder character-
ized by decreased bone mass, weakness and fragility [3].
The recommended daily intakes of Ca vary from 400 to 
1200 mg per day depending on age and gender; however, 
Abstract There is an ongoing controversy respecting cal-
cium supplementation and its role in osteoporosis treatment 
and prevention. Ca can be present in different forms that 
are likely to vary in their chemical properties and bioavail-
ability. This is the first study to investigate the bioavaila-
bility of calcium pyruvate (CaPyr) and to compare it with 
calcium citrate malate (CaCitrMalt) and calcium carbon-
ate (CaCarb).We performed a double-blind, four-arm, ran-
domized, placebo-controlled trial (crossover design with 
14-day washout) in which 1 g of Ca in each of these forms 
was administrated orally to 12 healthy postmenopausal 
women fasted prior to intervention. The greatest increase 
in serum Ca content was observed within the first 180 min 
although no statistically significant difference was found in 
the area under the plasma concentration curve between the 
studied supplement groups. The urinary Ca content in the 
0- to 12-h interval increased after CaCitrMalt and CaPyr 
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these needs are not always met in a traditional diet [4, 5]. 
Therefore, the use of dietary supplements containing Ca, 
as a method to prevent osteoporosis and other disorders 
related to Ca deficiency, is becoming increasingly popular 
[6]. Over the years, a variety of Ca formulas have become 
commercially available with most products based on car-
bonate or citrate form. The bioavailability of Ca from die-
tary supplements has been widely studied in recent years 
but remains controversial [7, 8]. Interestingly, the bioavail-
ability of Ca in the organic form of Ca pyruvate has not 
been studied so far. Pyruvate is known to play a pivotal 
role in various physiological processes, e.g., as the gateway 
between the glycolysis pathway and the Krebs cycle [9]. 
Therefore, as a counterion, it could affect the absorption of 
Ca through the epithelial cells and subsequently increase its 
availability.
The present study investigated Ca absorption from dif-
ferent compounds: pyruvate, citrate/malate as well as car-
bonate, and their effect on the intact parathyroid hormone 
(iPTH) level in a double-blind, four-arm, randomized, 
placebo-controlled trial. We also assessed the safety of the 
tested compounds and the potential side effects they may 
induce. This study adds to the general understanding of 
the role of Ca supplementation with various formulas in 
prevention of Ca deficiency and associated disorders, and 
demonstrates for the first time that pyruvate is a bioavail-
able form of Ca with a promising potential to prevent disor-
ders related to Ca deficiency.
Subjects and methods
Subjects
Twelve volunteers were recruited from the general popula-
tion of healthy postmenopausal women aged 45–60 years 
old, living in the City of Poznan´ (Poland, Europe). 
The exclusion criteria were as follows: overweight 
(BMI > 30 kg/m2), menstrual hemorrhage in the preceding 
6 months before participation in the study changes in hor-
mone replacement therapy (if present) during trial partici-
pation (3 months), diabetes, hyperparathyroidism, thyroid 
or other endocrine disorders, bone disease, nephrolithi-
asis, renal disease, peptic or duodenal ulcer, bowel disease, 
intestinal resection or malabsorption, regional enteritis, 
chronic diarrhea, liver disorder, cigarette smoking and alco-
holism. The exclusion criteria further included: uptake of 
any vitamin or mineral supplement, anticonvulsants, diu-
retics, steroids (other than hormone replacement therapy 
as described above), bisphosphonates or other medications 
that could affect calcium or vitamin D metabolism in the 
preceding 14 days before study day 1. To exclude par-
ticipants with major or long-lasting disturbances in bone 
metabolism, bone densitometry was performed using the 
DEXA method. All volunteers eligible for the study had 
a Z-score within the −1.0 to +1.0 range. The study was 
approved by the Bioethics Committee of Poznan Univer-
sity of Medical Sciences and was in conformance with the 
Declaration of Helsinki and CONSORT statement. Written 
informed consent was obtained from all participants before 
inclusion in the trial.
Tested calcium formulations and placebo
Three Ca formulations were used in this study: 5.80 g 
of pyruvate monohydrate (C6H6CaO6; CaPyr) contain-
ing 17.2 % of Ca [10], 4.23 g of citrate malate hydrate 
(C16H14Ca4O19; CaCitrMal) containing 23.7 % of Ca, and 
2.80 g of carbonate (CaCO3; CaCarb) containing 40 % of 
Ca. Content of Ca in each formulation corresponded to 
1 g of Ca2+. The placebo was composed of maltose. All 
compounds were placed in the form of powder in blinded 
sachets of identical appearance. Before administration, the 
whole content of each sachet was thoroughly suspended in 
150 mL of distilled water by stirring for 30 s.
Run‑in phases
Two weeks prior to the study, each volunteer was brought 
to Ca homeostasis through a daily intake of two doses of 
dietary supplement (Theva Pharmaceuticals, Poland) con-
taining 500 mg Ca (in form of CaCO3) and 200 IU of vita-
min D3 lasting for 11 days and followed by 2 days of a 
balanced diet to aid Ca absorption. This supplementation 
was undertaken to ensure that decreased Ca status would 
not alter its absorption rate during the intervention phase.
Intervention
To investigate the bioavailability of Ca in tested formula-
tions, twelve volunteers were included in the placebo-
controlled, randomized, four-way, four-period, repeated-
measures crossover study. A single oral dose of CaPyr, 
CaCitrMal, CaCarb or placebo was randomly assigned on 
study days 1, 14, 28 and 42 after a 12-h fasting period. The 
blinded random list was based upon 4 × 4 Latin squares 
(block size 4) and their mirror images (balanced design) 
and was not known to either investigators or volunteers 
until the end of the study. After administration, all volun-
teers were kept fasting and after 4, 6 and 10 h received a 
Ca-standardized breakfast, dinner and supper, respectively. 
The 100 mL of non-carbonized water uptake per hour was 
maintained. Urine samples were collected in fractions 
0–12 h and 12–4 h after administration. Venous blood sam-
ples were collected directly before administration (0 h) and 
1, 2, 3, 5, 6, 12 and 24 h afterward. All volunteers were 
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kept under observation by the investigators throughout the 
entire study period.
Analyses of Ca content in serum and urine
To estimate the bioavailability of Ca from orally ingested 
formulations, the content of the element was determined 
in urine and serum 1, 3, 5, 7, 12 and 24 h following the 
administration of each supplement. Levels of Ca were ana-
lyzed using a photometric assay performed at the Central 
Laboratory in the Gynecologic and Obstetrical Hospital in 
Poznan´, Poland, using a multi-analyte analyzer Cobas Inte-
gra 400 Plus (Roche Diagnostics Ltd., Switzerland). The 
laboratory is accredited annually by RIQAS (Randox Inter-
national Quality Assessment Scheme).
Analyses of intact parathyroid hormone content 
in serum
The content of intact parathyroid hormone (iPTH) in serum 
was estimated by a radioimmunological assay carried out in 
a routine diagnostics at an endocrinological laboratory 1, 3, 
7 and 24 h following the administration of each supplement.
Calculations and statistical analyses
Obtained data were analyzed using Proc MIXED of the 
statistical software SAS V9.2. Serum concentrations were 
transformed from mmol L−1 to mg dL−1 using the factor 
4.01 and ln-transformed before calculating the area under 
the plasma concentration–time curve (AUC) and maxi-
mum plasma concentration (Cmax). The parameters for 
AUC were confined to the area under the curve from time 
zero to the last measurement. The content of serum Ca 
and iPTH was presented as a percentage of the baseline 
level.
Results
Serum concentrations of Ca
The mean curves of serum Ca concentrations for each 
treatment phase (CaPyr, CaCitrMalt, CaCarb and placebo) 
revealed no statistically significant difference. An increase 
in Ca content was observed within the first 180 min of 
ingestion with the maximum values found for CaCitrMalt 
(Fig. 1). No differences in Cmax and AUC were found 
between the treated groups and the placebo although again, 
the maximum values were revealed after the ingestion of 
CaCitrMalt (Table 1).
Fig. 1  Changes in serum Ca concentration (mean ± SEM) follow-
ing administration of a placebo or 1000 mg of Ca as pyruvate, citrate 
malate or carbonate (n = 12)
Table 1  Pharmacokinetics variables calculated from serum total Ca 
concentrations in healthy postmenopausal women after a single oral 
dose of 1 g of Ca in different chemical formulas and placebos
CaPyr CaCitrMalt CaCarb Placebo
Cmax 0–5 h (LS-mean;  
mg dL−1)
4.95 5.10 5.03 4.92
Cmax 0–5 h
ratio placebo/treated
0.99 0.96 0.98 –
Cmax 0–12 h (LS-mean; 
mg dL−1)
4.93 5.10 5.02 4.85
Cmax 0–12 h
ratio placebo/treated
0.98 0.95 0.96 –
AUC0–12 h (LS-mean; 
mg dL−1)
57.25 58.73 57.84 57.01
AUC0–12 h
ratio placebo/treated
1.0 0.97 0.99 –
Table 2  Urinary excretion of Ca in healthy postmenopausal women 
after a single oral dose of 1 g of Ca in different chemical formulas 
and placebos
CaPyr CaCitrMalt CaCarb Placebo
0–12 h
 LS-mean (mg dL−1) 3.80 4.00 3.57 2.60
 Ratio
placebo/treated
0.69 0.65 0.73 –
12–24 h
 LS-mean (mg dL−1) 1.74 2.30 1.81 2.80
 Ratio
placebo/treated
1.62 1.22 1.54 –
0–24 h
 LS-mean (mg dL−1) 5.88 6.58 5.82 5.65
 Ratio
placebo/treated
0.96 0.86 0.97 –
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Urinary excretion of Ca
Compared to the placebo, the mean urinary concentrations 
of Ca between 0–12 h were significantly increased in the 
group treated with CaPyr and CaCitrMalt, but no such dif-
ference was noted for CaCarb. For the 12- to 24-h and 0- to 
24-h time intervals, Ca concentrations revealed no differ-
ences between the placebo and treatment groups. Moreo-
ver, the treatment groups also did not vary between each 
other (Table 2).
Parathyroid hormone level
All studied Ca supplements induced a decrease in iPTH. 
The most profound changes were found after administra-
tion of CaPyr and CaCarb (Fig. 2).
Side effects and adverse events
Following CaPyr ingestion, two volunteers reported adverse 
events characterized by gastrointestinal effects: dyspepsia 
and diarrhea. Additionally, one volunteer reported the same 
side effects following CaCitrMalt intake. No other adverse 
events were recorded. No patient was lost or withdrawn 
from the study.
Discussion
Supplementation of Ca has been commonly recommended 
for patients suffering from osteoporosis but also for the 
prevention of this disease in groups of increased risk, e.g., 
postmenopausal women [7, 11]. Commercial products 
manufactured to supplement this mineral vary in Ca form. 
Therefore, a study and comparison of their bioavailability 
and metabolism is essential. The present study demon-
strated that the tested Ca formulas, carbonate, pyruvate 
and citrate/malate, differ in bioavailability. CaCitrMalt 
increased Ca levels most significantly but revealed the 
greatest urinary excretion and the lowest effect on iPTH 
level. Thus, it can be assumed that CaCarb and CaPyr 
were the most effective in Ca supplementation. The study 
was, however, conducted on small number of subjects, and 
therefore, its results should be treated cautiously.
It should be emphasized that Ca supplementation may not 
always be beneficial for human health and it remains con-
troversial. As recognized by the general public, Ca supple-
mentation, apart from decreasing the risk of osteoporosis, 
may also have an impact on cancer prevention and play a 
role in the decrease in cardiovascular disorders [6, 12]. These 
assumptions are, however, only partially supported and 
require further studies [11, 13, 14]. Moreover, some studies 
support the view that Ca supplementation may even increase 
the risk of adverse cardiovascular events and have a dete-
riorating effect on lipid levels [15, 16]. To achieve realistic 
and comparable conditions in which both passive and active 
absorption pathways contribute significantly, in the present 
each supplement was administered in a dose of 1 g of Ca. It 
should, however, be noted that such daily supplementation at 
such concentration may finally adversely affect iron absorp-
tion [17]. Therefore, it would be desirable for such supple-
mentation to be subjected to ‘pro’s and con’s’ analyses prior 
to use and an evaluation made as to whether the potentially 
detrimental effects can be balanced against the likely benefits 
of calcium on bone [16, 18]. The aforementioned adverse 
events associated with Ca supplementation were, however, 
observed epidemiologically or in long-term (>half year) ran-
domized controlled trials. Our study had a short-term design 
and, as shown, both CaCitrMalt and CaPyr formulas induced 
dyspepsia and diarrhea. The latter has previously been 
reported for pyruvate compounds along with gas and bloat-
ing [19]. Although the prevalence of these symptoms was 
low in the studied group, the potential risk of gastrointesti-
nal events following the use of these supplements should be 
taken into account. To decrease the potential occurrence of 
side effects, it should be ensured that the manufactured prod-
uct is of the highest quality and purity [20].
Previous studies have shown that CaCitrMalt is likely to 
be more bioavailable than CaCarb [8, 21, 22]. These differ-
ences arise from the dependency of CaCarb solubility on an 
acidic environment, while CaCitrMalt has been shown to 
be partially soluble in water [23]. The present study is the 
first to compare the absorption of CaCitrMalt and CaCarb 
with CaPyr which is only slightly soluble in water [24]. As 
demonstrated in some previous investigations, CaPyr may 
have beneficial effects on health which include stimulation 
of weight and fat loss as well as improvement of exercise 
capacity, primarily in overweight individuals [25]. Hence, 
Fig. 2  Changes in serum iPTH levels (mean ± SEM) following 
administration of a placebo or 1000 mg of Ca as pyruvate, citrate 
malate or carbonate (n = 12)
49Eur Food Res Technol (2016) 242:45–50 
1 3
pyruvate has recently become a popular weight-loss sup-
plement and a performance-enhancing aid [26]. Neverthe-
less, these findings remain controversial and depend on the 
quality and stability issues of different CaPyr hydrates [27]. 
It has been demonstrated that CaPyr does not alter training 
adaptations without creatinine supplementation [25]. More-
over, Koh-Banerjee et al. [15] showed that not only does 
CaPyr supplementation not affect body composition dur-
ing training but it may even cancel some of the normally 
positive effects of exercise on blood lipid profiles. Further 
investigations are necessary to fully elucidate the mecha-
nism behind this observation.
As demonstrated in the present study, ingestion of a 
relatively high single dose of Ca (1000 mg) in the form 
of CaPyr, CaCitrMalt or CaCarb induced a slight increase 
in Ca blood levels within the studied time intervals. The 
greatest effect, also signified by Cmax and AUC values, 
was found for CaCitrMalt. In agreement with Hanzlik 
et al. [8], the increase in serum Ca content was the most 
significant only within the first few hours of ingestion. 
The oral use of CaCitrMalt also resulted in the greatest 
urinary excretion of Ca, whereas in case of CaPyr and 
CaCarb, excretion was nearly equal. Interestingly, CaPyr 
and CaCarb had the most profound effect on decreasing 
the iPTH levels. Considering its role in Ca regulation and 
use as biochemical marker of relative bioavailability of 
Ca from various products [1, 2], the lowered iPTH con-
tent following the administration of the studied Ca sup-
plements indicates that all of them, but particularly CaPyr 
and CaCarb may be useful in inhibiting the release of Ca 
from bone stores.
The maximum values of serum Ca content followed 
by significantly increased urine Ca levels following the 
ingestion of CaCitrMalt suggest that this form of Ca is the 
most readily absorbed form among those that were stud-
ied. CaPyr exhibited no competitive properties in Ca sup-
plementation with CaCitrMalt in this regard. This does not 
exclude its potential use in Ca supplementation, particu-
larly for subjects with low Ca dietary intakes or suffering 
from Ca deficiency although further clinical trials would be 
required to fully understand the potential of this forms in 
the treatment of Ca-associated alterations.
In summary, the present study demonstrated that sup-
plementation of CaCitrMalt exhibits the greatest absorp-
tion but also the most profound Ca loss with urine. In 
turn, administration of CaPyr and CaCarb leads to the 
most effective decrease in iPTH in the short term. No seri-
ous side effects were noted following a single dosage of 
each supplement although two individuals developed mild 
gastrointestinal events after CaPyr use. However, CaPyr 
demonstrates a promising source of Ca and a potential 
for use in osteoporosis prevention. Further investigations 
should focus on the long-term dietary effects of CaPyr 
supplementation to assess its safety and potential beneficial 
effect on human Ca turnover.
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